` LXRX (Lexicon Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

LXRX
vs
S&P 500

Over the past 12 months, LXRX has underperformed S&P 500, delivering a return of -27% compared to the S&P 500's +15% growth.

Stocks Performance
LXRX vs S&P 500

Loading
LXRX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
LXRX vs S&P 500

Loading
LXRX
S&P 500
Difference
www.alphaspread.com

Performance By Year
LXRX vs S&P 500

Loading
LXRX
S&P 500
Add Stock

Competitors Performance
Lexicon Pharmaceuticals Inc vs Peers

S&P 500
LXRX
ABBV
AMGN
GILD
VRTX
Add Stock

Lexicon Pharmaceuticals Inc
Glance View

Market Cap
450.6m USD
Industry
Biotechnology

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.

LXRX Intrinsic Value
1.02 USD
Overvaluation 18%
Intrinsic Value
Price
Back to Top